Pemvidutide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Steatohepatitis (NASH)
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Trial Timeline
Jul 27, 2023 → Nov 25, 2025
NCT ID
NCT05989711About Pemvidutide + Placebo
Pemvidutide + Placebo is a phase 2 stage product being developed by Altimmune for Non-Alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT05989711. Target conditions include Non-Alcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 4 similar drugs in Non-Alcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05989711 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Alcoholic Steatohepatitis (NASH)